All articles tagged with #akero therapeutics
Originally Published 3 months ago — by Investor's Business Daily
Novo Nordisk is acquiring Akero Therapeutics for $4.7 billion to expand its portfolio in obesity-related treatments, focusing on Akero's experimental drug efruxifermin for liver disease, which shows promise in reducing fibrosis in patients with cirrhosis, addressing a significant unmet medical need.
Originally Published 3 months ago — by TipRanks
Novo Nordisk acquired Akero Therapeutics for $5.2 billion, causing AKRO stock to jump 19%, highlighting a significant M&A deal in the biotech sector.
Originally Published 3 months ago — by CNBC
Novo Nordisk's shares declined 2.4% after announcing a $4.7 billion acquisition of U.S. biotech firm Akero Therapeutics, which saw its shares rise 19.6% pre-market; the deal includes a contingent value right that could add $500 million. The market also responded to HSBC's privatization bid for Hang Seng Bank, European tariff changes, political developments in France, and significant moves in Asian and U.S. markets.
Originally Published 2 years ago — by Investor's Business Daily
Shares of Akero Therapeutics (AKRO) and 89bio (ETNB) plummeted after Akero's liver-disease treatment failed to meet expectations in a midstage study. While the drug showed statistically significant results in resolving NASH, the improvement in liver scarring was not statistically significant. Despite this, analysts believe that the effectiveness data sets for both companies are strong, with 89bio potentially pulling ahead due to its dosing schedule and lower side effects. Akero shares fell 64% and 89bio shares tumbled 36.6% as a result of the news.
Originally Published 2 years ago — by CNBC
Xpeng's U.S.-traded shares rose 5% premarket after announcing the acquisition of Didi's smart electric car business for $744 million. 3M saw a rally of over 5% as it tentatively agreed to settle more than 330,000 lawsuits related to defective earplugs for over $5.5 billion. Mister Car Wash stock climbed 5.7% following an upgrade by Piper Sandler, while CrowdStrike shares fell 2.6% after a downgrade by Morgan Stanley. Akero Therapeutics gained 2.2% as UBS initiated coverage with a buy rating. Additionally, Chinese stocks Alibaba and JD.com rose after the Chinese government announced measures to boost its stock market. RPT Realty surged over 11% as it is being acquired by Kimco Realty for $2 billion in stock, and Abcam fell over 3% after Danaher announced its acquisition in a deal valued at around $5.7 billion. Boston Scientific jumped 5.5% after positive results for its treatment for patients with abnormal heartbeats.